JP2017523781A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523781A5
JP2017523781A5 JP2017505552A JP2017505552A JP2017523781A5 JP 2017523781 A5 JP2017523781 A5 JP 2017523781A5 JP 2017505552 A JP2017505552 A JP 2017505552A JP 2017505552 A JP2017505552 A JP 2017505552A JP 2017523781 A5 JP2017523781 A5 JP 2017523781A5
Authority
JP
Japan
Prior art keywords
aptamer
nucleic acid
seq
dimer
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017505552A
Other languages
English (en)
Japanese (ja)
Other versions
JP6680760B2 (ja
JP2017523781A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043162 external-priority patent/WO2016019270A1/en
Publication of JP2017523781A publication Critical patent/JP2017523781A/ja
Publication of JP2017523781A5 publication Critical patent/JP2017523781A5/ja
Application granted granted Critical
Publication of JP6680760B2 publication Critical patent/JP6680760B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017505552A 2014-07-31 2015-07-31 アンタゴニストic pd−1アプタマー及びその癌治療関連用途への応用 Expired - Fee Related JP6680760B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462031427P 2014-07-31 2014-07-31
US62/031,427 2014-07-31
PCT/US2015/043162 WO2016019270A1 (en) 2014-07-31 2015-07-31 An antagonistic pd-1 aptamer and its applications in cancer therapy related applications

Publications (3)

Publication Number Publication Date
JP2017523781A JP2017523781A (ja) 2017-08-24
JP2017523781A5 true JP2017523781A5 (OSRAM) 2018-09-13
JP6680760B2 JP6680760B2 (ja) 2020-04-15

Family

ID=55218360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017505552A Expired - Fee Related JP6680760B2 (ja) 2014-07-31 2015-07-31 アンタゴニストic pd−1アプタマー及びその癌治療関連用途への応用

Country Status (8)

Country Link
US (1) US10329570B2 (OSRAM)
EP (1) EP3174985A4 (OSRAM)
JP (1) JP6680760B2 (OSRAM)
KR (1) KR20170055474A (OSRAM)
CN (1) CN107002083A (OSRAM)
CA (1) CA2956718A1 (OSRAM)
TW (1) TWI703214B (OSRAM)
WO (1) WO2016019270A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1248115A1 (zh) 2015-07-16 2018-10-12 Bioxcel Therapeutics, Inc. 一种使用免疫调节治疗癌症的新颖方法
US11219635B2 (en) 2016-02-19 2022-01-11 City Of Hope Bi-specific aptamer
WO2018048888A1 (en) * 2016-09-06 2018-03-15 The Methodist Hospital System Pd-1 specific aptamers
US10889816B2 (en) * 2016-09-16 2021-01-12 Duke University Von Willebrand Factor (VWF)—targeting agents and methods of using the same
CN107794267B (zh) * 2017-03-14 2021-03-26 湖南大学 一种靶向pd1-pdl1的双特异性核酸适体及其衍生物
EP3664814A4 (en) 2017-08-11 2021-05-05 City of Hope Rna aptamers against transferrin receptor (tfr)
US11007211B2 (en) * 2018-01-07 2021-05-18 City Of Hope CCR7 aptamers and uses thereof
EP3683310A1 (en) 2019-01-21 2020-07-22 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer and use of the aptamer in the diagnosis and treatment of cancer
CN111154765B (zh) * 2019-12-30 2023-08-01 广西医科大学 T细胞免疫检查点pd-1的适配体筛选、鉴定方法及抗肿瘤应用
US20230117328A1 (en) 2020-03-03 2023-04-20 Array Biopharma Inc. Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
CN111593053B (zh) * 2020-05-27 2022-02-15 武汉大学 识别人程序性死亡受体1的dna适配体及方法和应用
US20240417738A1 (en) * 2021-10-22 2024-12-19 Ohio State Innovation Foundation Immunotherapies for the treatment of cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU1959897A (en) * 1996-02-22 1997-09-10 Board Of Trustees Of Michigan State University Gene specific universal mammalian sequence-tagged sites
EP1268856A2 (de) * 2000-04-07 2003-01-02 Epigenomics AG Detektion von snp's und cytosin-methylierungen
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20040180360A1 (en) 2002-11-21 2004-09-16 Charles Wilson Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
EP2623601B1 (en) 2003-04-21 2015-02-18 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2617782A1 (en) * 2005-08-26 2007-03-01 Archemix Corp. Aptamers that bind thrombin with high affinity
WO2007136989A2 (en) * 2006-05-05 2007-11-29 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of dgat2
US8835111B2 (en) * 2009-03-12 2014-09-16 Brainco Biopharma S.L. Genotyping tool for improving the prognostic and clinical management of MS patients
US20130209514A1 (en) * 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
EP2354247A1 (en) * 2010-02-11 2011-08-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for typing a sample for rheumatoid arthritis or spondyloarthritis
WO2013012921A2 (en) * 2011-07-20 2013-01-24 University Of Iowa Research Foundation Nucleic acid aptamers
BR112014020164B1 (pt) * 2012-02-16 2022-09-13 Syngenta Participations Ag Polipeptídeo pesticida vip3 manipulado, molécula de ácido nucleico, vetor e composição
WO2013142255A2 (en) 2012-03-22 2013-09-26 University Of Miami Multi-specific binding agents
JP2015518713A (ja) * 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Utrn発現を調節するための組成物及び方法
EP2912182B1 (en) * 2012-10-23 2021-12-08 Caris Science, Inc. Aptamers and uses thereof
HK1214628A1 (zh) * 2012-11-05 2016-07-29 Pronai Therapeutics, Inc. 寡核苷酸癌症療法的給藥和施用
CA2892490A1 (en) * 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
US11254933B2 (en) * 2014-07-14 2022-02-22 The Regents Of The University Of California CRISPR/Cas transcriptional modulation

Similar Documents

Publication Publication Date Title
JP2017523781A5 (OSRAM)
Luo et al. Biodegradable multiblock poly [N-(2-hydroxypropyl) methacrylamide] via reversible addition− fragmentation chain transfer polymerization and click chemistry
Zhou et al. Engineering and delivery of cGAS-STING immunomodulators for the immunotherapy of cancer and autoimmune diseases
CY1123978T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf
JP2016521688A5 (OSRAM)
CN102920649B (zh) 载药纳米胶束及其制备方法和应用
JP2013515745A5 (OSRAM)
JP2019513118A5 (OSRAM)
EP4461739A3 (en) Bicyclic peptide ligands specific for nectin-4
JP2018015005A5 (OSRAM)
JP2012255007A5 (OSRAM)
JP2016153410A5 (OSRAM)
JP2016502515A5 (OSRAM)
FI3430027T3 (fi) Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa
JP2014520120A5 (OSRAM)
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
JP2019531093A5 (OSRAM)
JP2014526881A5 (OSRAM)
JP2012509902A5 (OSRAM)
JP2017528444A5 (OSRAM)
Kasala et al. Utilizing adenovirus vectors for gene delivery in cancer
JP2017501130A5 (OSRAM)
WO2012012352A3 (en) Modified peptides and proteins
JP2011511773A5 (OSRAM)
JP2013513377A5 (OSRAM)